TOPOI/PARP-1-IN-1

TOPOI/PARP-1-IN-1 (Compound B6) is an orally active, low cytotoxic TOPOI/PARP dual inhibitor with an IC50 value of 0.09 μM for PARP1. TOPOI/PARP-1-IN-1 can effectively inhibit the proliferation and migration of cancer cells. TOPOI/PARP-1-IN-1 also causes cell cycle arrest in the G0/G1 phase and induces apoptosis. The tumor growth inhibition rate (TGI) of TOPOI/PARP-1-IN-1 in mice is 75.4%[1].

Product Specifications

CAS Number

[2948352-16-5]

UNSPSC

12352005

Target

Apoptosis; PARP; Topoisomerase

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/topoi-parp-1-in-1.html

Solubility

10 mM in DMSO

Smiles

O=C(N([C@@]([H])([C@]1(CCCN2CCC3)[H])CCCC4=NC(C=C(C(Br)=C5)Br)=C5N4)C[C@@]3([H])[C@@]12[H])OCC6C7=C(C8=C6C=CC=C8)C=CC=C7

Molecular Formula

C36H38Br2N4O2

Molecular Weight

718.52

References & Citations

[1]Qiu G, et al. Design, synthesis and biological evaluation of matrine contains benzimidazole derivatives as dual TOPOI and PARP inhibitors for cancer therapy. Eur J Med Chem. 2024 Mar 27;270:116348.